BRD4 and metabolic dysfunction-associated steatohepatitis: Accordingly, the inhibition of the H3K27ac reader, the bromodomain-containing protein 4 (BRD4), with the small-molecule JQ1 reverted the bad prognosis-associated transcriptional program in HCC cells, and significantly reduced tumor burden in a mouse model of NASH-induced hepatocarcinogenesis [48].